Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 11/20 | 0.54 |
| ▸ | MMP3 | P08254 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 1/20 | 0.54 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 1/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29432617 | 0.93 | REN (0.53) | RENMMP3CTSBCTSKMME | |
| SCHEMBL20257141 | 0.89 | CTSK (0.56) | RENCTSBCTSKCAPN1 | |
| SCHEMBL23133192 | 0.89 | CTSK (0.56) | RENCTSBCTSKCAPN1 | |
| SCHEMBL29392130 | 0.88 | NMBR (0.58) | REN | |
| SCHEMBL23133281 | 0.86 | REN (0.48) | RENCTSBCTSKCAPN1 | |
| SCHEMBL20257155 | 0.86 | REN (0.48) | RENCTSBCTSKCAPN1 | |
| SCHEMBL20257150 | 0.84 | CTSK (0.51) | RENCTSBCTSKCAPN1 | |
| SCHEMBL21481101 | 0.84 | CTSK (0.56) | RENCTSBCTSKCAPN1 | |
| SCHEMBL21481102 | 0.84 | CTSK (0.56) | RENCTSBCTSKCAPN1 | |
| SCHEMBL23613619 | 0.84 | CTSL (0.48) | RENCTSBCTSKCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240365773-A1 | USE OF APOPTOSIS INHIBITORS FOR COLD STORAGE OF BLOOD PLATELETS | ZENTRUM FÜR KLINISCHE TRANSFUSIONSMEDIZIN TÜBINGEN GGMBH (ZKT) (DE) | 2024-11-07 | — | — | US | claimed |
| CN-118120736-A | Intestinal tissue preservation solution and preservation method and application thereof | 江苏齐氏生物科技有限公司 | 2024-06-04 | — | — | CN | claimed |
| CN-118044505-A | Fresh tissue preservation solution and preparation method and application thereof | 北京百奥智汇科技有限公司 | 2024-05-17 | — | — | CN | claimed |
| US-20240115649-A1 | CASPASE INHIBITION TO ENHANCE REGENERATION AND REPAIR AFTER SKIN OR GUT INJURY AND TO TREAT BACTERIAL OR VIRAL INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-04-11 | — | — | US | claimed |
| EP-4326060-A1 | USE OF APOPTOSIS INHIBITORS FOR COLD STORAGE OF BLOOD PLATELETS | DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH (DE) | 2024-02-28 | — | — | EP | claimed |
| US-11618883-B2 | Method for producing retinal pigment epithelial cells | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-04 | — | — | US | claimed |
| WO-2022223815-A1 | USE OF APOPTOSIS INHIBITORS FOR COLD STORAGE OF BLOOD PLATELETS | DRK BLUTSPENDEDIENST BADEN-WÜRTTEMBERG-HESSEN GGMBH (DE) | 2022-10-27 | — | — | WO | claimed |
| EP-4079154-A1 | USE OF APOPTOSIS INHIBITORS FOR COLD STORAGE OF BLOOD PLATELETS | DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH (DE) | 2022-10-26 | — | — | EP | claimed |
| CN-115197913-A | Primary corneal endothelial cell culture solution and application thereof | 江苏齐氏生物科技有限公司 | 2022-10-18 | — | — | CN | claimed |
| CN-114586768-A | Liver tissue preservation solution and preservation method and application thereof | 江苏齐氏生物科技有限公司 | 2022-06-07 | — | — | CN | claimed |
| EP-4709405-A2 | FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS | Alume Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250216377-A1 | COMPOSITIONS AND METHODS FOR DETECTING CARDIOTOXICITY | AGEX THERAPEUTICS, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| US-12344599-B2 | Prodigiosin analogs and methods of use | INSTITUTE FOR CANCER RESEARCH (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2025128913-A1 | INHIBITION OF ENDOSOMAL ESCAPE DETECTION TO AMELIORATE THE INFLAMMATORY SIDE-EFFECTS OF LIPID NANOPARTICLES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20220118101-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR REDUCING INFLAMMATION BY INHIBITING CASPASE-9 | UNIV COLUMBIA (US) | 2022-04-21 | — | — | US | disclosed |
| US-11299515-B2 | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-12 | — | — | US | disclosed |
| CN-107921094-B | IGFBP3 and uses thereof | 圣拉斐尔医院有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-11246940-B2 | Peptides whose uptake in cells is controllable | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-15 | — | — | US | disclosed |
| US-20220033382-A9 | Prodigiosin Analogs And Methods Of Use | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344599-B2 | Prodigiosin analogs and methods of use | TP53, MCL1, TP53BP1 | REN 4017/4885MMP3 1564/4885CTSB 297/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | REN 3526/4885MMP3 2597/4885CTSB 4255/4885 |
| US-20220033382-A9 | Prodigiosin Analogs And Methods Of Use | TP53, MCL1, TP53BP1 | REN 4017/4885MMP3 1564/4885CTSB 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.